Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sepsis, Severe Clear all
Completed Not applicable Interventional

Predictive algoRithm for EValuation and Intervention in SEpsis

NCT03235193
View directory record Official record
Conditions
Sepsis, Septic Shock, Severe Sepsis
Interventions
Severe Sepsis Prediction, Severe Sepsis Detection
Other
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
2,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jun 26, 2026, 7:22 AM EDT
Completed No phase listed Observational

Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis

NCT00185783
View directory record Official record
Conditions
Sepsis, Relative Adrenal Insufficiency
Interventions
Hydrocortisone Administration (Standard of Care Therapy)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Jun 26, 2026, 7:22 AM EDT
Suspended Phase 2Phase 3 Interventional

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Not applicable Interventional

ED Tracking Sheet Implementation

NCT05213923
View directory record Official record
Conditions
Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
Interventions
ED Sepsis Tracking Sheet
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jun 26, 2026, 7:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Measurement of Reactive Hyperemia in Critical Care

NCT01726595
View directory record Official record
Conditions
Severe Sepsis, Critical Illness
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

NCT00630656
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Loma Linda, California • Sacramento, California • Sylmar, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Jun 26, 2026, 7:22 AM EDT
Recruiting Not applicable Interventional

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

NCT05975671
View directory record Official record
Conditions
Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy, Sepsis, Severe, Septic Shock, Septic Syndrome
Interventions
Multifaceted de-implementation strategy to reduce vancomycin overuse
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
52,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 26, 2026, 7:22 AM EDT
Completed No phase listed Observational

The AVERT Sepsis Investigation

NCT01968746
View directory record Official record
Conditions
Sepsis, Severe Sepsis
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Denver, Colorado • Newark, Delaware • Billings, Montana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 4 Interventional

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

NCT00045760
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
152
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Jun 26, 2026, 7:22 AM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

NCT00016523
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 120 Hours
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Not applicable Interventional

Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis

NCT01484106
View directory record Official record
Conditions
Sepsis
Interventions
Fluid Resuscitation, Standard of Care
Other
Lead sponsor
Cheetah Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Sacramento, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT02640807
View directory record Official record
Conditions
Severe Sepsis With Septic Shock
Interventions
Interleukin-7, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jun 26, 2026, 7:22 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jun 26, 2026, 7:22 AM EDT
Completed No phase listed Observational

Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital

NCT04819035
View directory record Official record
Conditions
Sepsis, Adult Disease, Severe Sepsis, Emergency Department
Interventions
CBC-DIFF Monocyte Volume Width Distribution (MDW)
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Results available

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

NCT02203019
View directory record Official record
Conditions
Sepsis, Respiratory Failure, Agitation
Interventions
Propofol, Dexmedetomidine, Fentanyl
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 26, 2026, 7:22 AM EDT
Not listed No phase listed Observational

Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19

NCT05060250
View directory record Official record
Conditions
Severe Sepsis
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Acton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

NCT01689441
View directory record Official record
Conditions
Severe Sepsis or Septic Shock
Interventions
Calcitriol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jun 26, 2026, 7:22 AM EDT
Terminated No phase listed Observational

Muscle Atrophy in Patients With Severe Sepsis

NCT01717651
View directory record Official record
Conditions
Severe Sepsis, Respiratory Failure
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jun 26, 2026, 7:22 AM EDT
Completed No phase listed Observational

Mitochondrial DNA as a Biomarker of Sepsis Severity

NCT03077672
View directory record Official record
Conditions
Sepsis Syndrome, Sepsis, Severe Sepsis, Septic Shock, Infection
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 4 Interventional

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

NCT00067730
View directory record Official record
Conditions
Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
Interventions
Drotrecogin Alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Manhassaet, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Jun 26, 2026, 7:22 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Intravenous Ascorbic Acid in Severe Sepsis

NCT02734147
View directory record Official record
Conditions
Sepsis
Interventions
Ascorbic Acid, Normal Saline
Drug · Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jun 26, 2026, 7:22 AM EDT
Recruiting Not applicable Interventional

Assessment for Implementation Methods in Sepsis

NCT05491941
View directory record Official record
Conditions
Sepsis Severe, Septic Shock
Interventions
Sepsis Bundle
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

NCT01739933
View directory record Official record
Conditions
Sepsis, Delirium, Impaired Cognition
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
San Francisco, California • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jun 26, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

NCT00089986
View directory record Official record
Conditions
Sepsis
Interventions
Intravenous GR270773- Phospholipid Emulsion, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
132
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jun 26, 2026, 7:22 AM EDT